

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 317/44, 317/46, C07D 295/18, A61K 31/10	A1	(11) International Publication Number: WO 97/28120 (43) International Publication Date: 7 August 1997 (07.08.97)
(21) International Application Number: PCT/CA97/00063 (22) International Filing Date: 29 January 1997 (29.01.97) (30) Priority Data: 60/010,950 1 February 1996 (01.02.96) US 9605647.8 18 March 1996 (18.03.96) GB (71) Applicant (for all designated States except US): MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): BLACK, Cameron [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GIRARD, Mario [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GUAY, Daniel [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). WANG, Zhaoyin [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). (74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Québec H3A 2Y3 (CA).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: DIPHENYL STILBENES AS PRODRUGS TO COX-2 INHIBITORS**(57) Abstract**

The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

TITLE OF THE INVENTION**DIPHENYL STILBENES AS PRODRUGS TO COX-2 INHIBITORS****BACKGROUND OF THE INVENTION**

5

This invention relates to methods of treating cyclooxygenase mediated diseases and certain pharmaceutical compositions therefor.

Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-
10 induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Initially, only one form of cyclooxygenase was known, this corresponding to cyclooxygenase-1 (COX-1) or the constitutive enzyme, as originally identified in bovine seminal vesicles. More recently the
15 gene for a second inducible form of cyclooxygenase, cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources. This enzyme is distinct from the COX-1 which has been cloned, sequenced and characterized from various sources including the sheep, the mouse and man. The second form of
20 cyclooxygenase, COX-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, COX-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the
25 maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, COX-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as
30 inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of COX-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a


- 2 -

diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce
 5 asthma attacks in aspirin-sensitive asthmatic subjects.


Furthermore, such a compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders.
 10 It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women (i.e. treatment of osteoporosis) and for the treatment of glaucoma.

A brief description of the potential utility of cyclooxygenase-2 inhibitors is given in an article by John Vane, Nature,
 15 Vol. 367, pp. 215-216, 1994, and in an article in Drug News and Perspectives, Vol. 7, pp. 501-512, 1994.

A number of stilbene derivatives are known in the chemical literature. Toda *et al.*, in *Chem. Commun.* 1234-5 (1984) describe the
 20 dialdehydes A and the diol B is described by Tsuji *et al.*, *J. Am. Chem. Soc.* 88, 1289-92 (1966), and diol C was prepared by Dhawau *et al.*, *J. Org. Chem.*, 45, 922-4 (1980). No utility is disclosed for these compounds, nor do they carry the R¹ substituent of the present invention.




A
 X = H or Cl



B X = H Tsuji
 C X = Cl Dhawan

- 3 -

Structure D is disclosed as having usefulness for treating hyperlipidemia by Hashimoto *et al.*, European Patent Application 424,541 (May 2, 1991).



X, Y are halogen

R is C₁₋₆ alkyl


n is 0, 1 or 2

D

- 5 These compounds (D) lack the second carbon substituent X of the present invention and have an unrelated utility.

SUMMARY OF THE INVENTION

- 10 The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. These compounds are prodrugs of compounds which inhibit COX-2 selectively over COX-1. The prodrugs are converted *in vivo* to the selective
- 15 inhibitors.



I


- 4 -

The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

5 DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of

10 Formula I



I

or pharmaceutically acceptable salts thereof wherein

15

X is

- (a) CH_2OH ,
- (b) CHO ,
- (c) CO_2R^4 , or
- 20 (d) CONR^4_2 ;

Y is

- (a) CH_3 , or
- (b) CH_2OR^5 ;

R^1 is selected from the group consisting of

25

- (a) $\text{S(O)}_2\text{CH}_3$,
- (b) $\text{S(O)}_2\text{NH}_2$,
- (c) $\text{S(O)}_2\text{NHC(O)CF}_3$,
- (d) S(O)(NH)CH_3 ,
- (e) S(O)(NH)NH_2 ,

- 5 -

- (f) $\text{S(O)(NH)NHC(O)CF}_3$,
- (g) $\text{P(O)(CH}_3\text{)OH}$, and
- (h) $\text{P(O)(CH}_3\text{)NH}_2$;

5 R^2 and R^3 each are independently selected from the group consisting of

- (a) hydrogen,
- (b) halo,
- (c) C_{1-6} alkoxy,
- (d) C_{1-6} alkylthio,
- 10 (e) CN ,
- (f) CF_3 ,
- (g) C_{1-6} alkyl, and
- (h) N_3 ;

R^4 is selected from the group consisting of

- 15 (a) hydrogen,
- (b) C_{1-6} alkyl, and
- (c) mono- or disubstituted benzyl wherein the substituent is
 selected from
 - 20 (1) hydrogen,
 - (2) halo,
 - (3) C_{1-6} alkyl,
 - (4) C_{1-6} alkoxy,
 - (5) C_{1-6} alkylthio,
 - (6) OH ,
 - 25 (7) CN , and
 - (8) CF_3 ,

 or two R^4 groups joined to the same N can form a saturated
 5, 6 or 7-membered ring optionally containing an O or
 S or an additional N atom, said N atom substituted by
30 a hydrogen or C_{1-6} alkyl;

R^5 is selected from the group consisting of

- (a) C_{1-6} alkyl,
- (b) mono- or disubstituted benzyl wherein the substituent is
 selected from
 - 35 (1) hydrogen,

- 6 -

- 5 (2) halo,
 (3) C₁₋₆alkyl,
 (4) C₁₋₆alkoxy,
 (5) C₁₋₆alkylthio,
 (6) OH,
 (7) CN,
 (8) CF₃, and
 (9) CO₂R⁴.
- 10 In one genus, preferred compounds within this embodiment
are those wherein
R¹ is selected from the group consisting of
 (a) S(O)₂CH₃, and
 (b) S(O)₂NH₂;
- 15 R² and R³ are each independently selected from the group consisting of
 (1) hydrogen,
 (2) halo, selected from the group consisting of fluoro, chloro and
bromo.
- 20 In another genus, preferred compounds within this
embodiment are those wherein
Y is CH₃ or CH₂OC₁₋₆alkyl.
- Within this genus is the class of compounds wherein
- 25 Y is CH₃ or CH₂OC₁₋₆alkyl;
R¹ is selected from the group consisting of
 (a) S(O)₂CH₃,
 (b) S(O)₂NH₂,
 (c) S(O)₂NHC(O)CF₃,
30 (d) S(O)NHCH₃,
 (e) S(O)NHNH₂, and
 (f) S(O)NHNHC(O)CF₃; and
R² and R³ are each independently selected from the group consisting of
 (a) hydrogen,
35 (b) fluoro, chloro, and bromo,

- 7 -

- 5 (c) C₁₋₄alkoxy,
(d) C₁₋₄alkylthio,
(e) CN,
(f) CF₃, and
(g) C₁₋₄alkyl.

Within this class is the sub-class of compounds wherein R² and R³ are each independently selected from the group consisting of

- 10 (1) hydrogen, and
(2) halo;
R⁴ is hydrogen or methyl; and
R⁵ is C₁₋₆alkyl.

- 15 In another genus, preferred compounds within the above embodiment are those wherein X is CO₂R⁴.

- Within this genus is the class of compounds wherein X is CO₂R⁴;
20 Y is methyl or CH₂OR⁵;
R¹ is S(O)₂CH₃;
R² and R³ each are independently selected from the group consisting of
(a) hydrogen, and
(b) halo;
25 R⁴ is selected from the group consisting of
(a) hydrogen, and
(b) C₁₋₆alkyl,
R⁵ is selected from the group consisting of
(a) C₁₋₆alkyl,
30 (b) mono- or disubstituted benzyl wherein the substituent is selected from
(1) hydrogen,
(2) halo,
(3) C₁₋₆alkoxy, and
35 (4) OH.

- 8 -

Within this class is the sub-class of compounds wherein

X is CO₂R⁴;

Y is methyl or CH₂OR⁵;

5 R¹ is S(O)₂CH₃;

R² and R³ each are independently selected from the group consisting of

(a) hydrogen, and

(b) halo;

R⁴ is selected from the group consisting of

10 (a) hydrogen, and

(b) C₁-6alkyl,

R⁵ is selected from the group consisting of

(a) C₁-6alkyl,

15 (b) mono- or disubstituted benzyl wherein the substituent is selected from

(1) hydrogen,

(2) halo,

(3) C₁-6alkoxy, and

(4) OH.

20

Illustrating the invention are the compounds of Tables II and

III.

25 For purposes of this specification alkyl is defined to include linear, branched, and cyclic structures, with the indicated number of carbon atoms. Examples of alkyl are methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly alkoxy and alkylthio means linear, branched and cyclic structures with the indicated number of carbon atoms.

30 For purposes of this specification, where a definition appears twice, such as "R⁴" in "CONR⁴₂" each occurrence is to be considered independent of each other occurrence. Thus, in "CONR⁴₂", the "R⁴" groups need not be identical.

- 9 -

For purposes of this specification Halo means F, Cl, Br, or I.

The following abbreviations have the indicated meanings:

5	AA	=	arachidonic acid
	Ac	=	acetyl
	AIBN	=	2,2--azobisisobutyronitrile
	Bn	=	benzyl
	CHO	=	chinese hamster ovary
10	CMC	=	1-cyclohexyl-3-(2-morpholinoethyl) carbodiimidemetho- <i>p</i> -toluenesulfonate
	COX	=	cyclooxygenase
	DBU	=	diazabicyclo[5.4.0]undec-7-ene
	DMAP	=	4-(dimethylamino)pyridine
15	DMF	=	N,N-dimethylformamide
	DMSO	=	dimethyl sulfoxide
	Et ₃ N	=	triethylamine
	HBSS	=	Hanks balanced salt solution
20	HEPES	=	N-[2-Hydroxyethyl]piperazine-N ¹ -[2- ethanesulfonic acid]
	HWB	=	human whole blood
	KHMDS	=	potassium hexamethyldisilazane
	LDA	=	lithium diisopropylamide
	LPS	=	lipopolysaccharide
25	mCPBA	=	metachloro perbenzoic acid
	MMPP	=	magnesium monoperoxyphthalate
	Ms	=	methanesulfonyl = mesyl
	MsO	=	methanesulfonate = mesylate
30	NBS	=	N-bromosuccinimide
	NCS	=	N-chlorosuccinimide
	NIS	=	N-iodosuccinimide
	NSAID	=	non-steroidal anti-inflammatory drug
	Oxone®	=	potassium peroxymonosulfate
35	PCC	=	pyridinium chlorochromate
	PDC	=	pyridinium dichromate
	r.t.	=	room temperature
	rac.	=	racemic
	Tf	=	trifluoromethanesulfonyl = triflyl
	TFAA	=	trifluoroacetic anhydride
40	TfO	=	trifluoromethanesulfonate = triflate
	THF	=	tetrahydrofuran

- 10 -

	TLC	=	thin layer chromatography
	TMPD	=	N,N,N',N'-tetramethyl-p-phenylenediamine
	Ts	=	p-toluenesulfonyl = tosyl
	TsO	=	p-toluenesulfonate = tosylate
5	Tz	=	1H (or 2H)-tetrazol-5-yl
	SO ₂ Me	=	methyl sulfone (also SO ₂ CH ₃)
	SO ₂ NH ₂	=	sulfonamide

	<u>Alkyl group abbreviations</u>		<u>Dose Abbreviations</u>	
10	Me	=	methyl	bid = bis in die = twice daily
	Et	=	ethyl	qid = quater in die = four times a day
	n-Pr	=	normal propyl	tid = ter in die = three times a day
15	i-Pr	=	isopropyl	
	n-Bu	=	normal butyl	
	i-Bu	=	isobutyl	
	s-Bu	=	secondary butyl	
	t-Bu	=	tertiary butyl	
20	c-Pr	=	cyclopropyl	
	c-Bu	=	cyclobutyl	
	c-Pen	=	cyclopentyl	
	c-Hex	=	cyclohexyl	

25 Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

30 Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

35 The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis,

- 11 -

including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumour growth and hence
5 can be used in the treatment of cancer. Compound 1 may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumour angiogenesis.

Compound I, by virtue of its *in vivo* conversion to a COX-2
10 inhibitor, will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in
15 postmenopausal women (i.e. treatment of osteoporosis), and for treatment of glaucoma.







The compounds of Formula I are prodrugs of selective COX-2 inhibitors, and exert their action by conversion *in vivo* to these active and selective COX-2 inhibitors. The active compounds
20 formed from the compounds of the present invention are described in the following documents which are hereby incorporated by reference:

WO 95/00501, published January 5, 1995, WO 95/18799, published July 13, 1995 and U.S. patent 5,474,995, published December 12, 1995.

25 In certain respects, compounds of the present invention have advantages over the compounds described in these documents by virtue of improved pharmacokinetic and/or safety profiles. A general description of the advantages and uses of prodrugs as pharmaceutically useful compounds is given in an article by Waller and
30 George in Br. J. Clin. Pharmac. Vol. 28, pp. 497-507, 1989.

By way of illustration, the following compounds of the present invention are converted to the indicated COX-2 selective inhibitors.

- 12 -

Example	Prodrug	Active Drug	Reference
1			U.S. Pat. 5,474,995
2			U.S. Pat. 5,474,995
3			U.S. Pat. 5,474,995

5 By virtue of its *in vivo* conversion to a compound with high inhibitory activity against COX-2 and/or a specificity for COX-2 over COX-1, compound I will prove useful as an alternative to conventional NSAID'S, particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis,

10 regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anaemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking anticoagulants.

15 The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts

- 13 -

prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the
5 like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine,
10 choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins,
15 procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like, and basic ion exchange resins.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are
20 meant to also include the pharmaceutically acceptable salts.

The compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache,
25 toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence
30 can be used in the treatment of cancer. Compound I may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumour angiogenesis.

- 14 -

Compound I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, and for the prevention of bone loss (treatment of osteoporosis) and for the treatment of glaucoma.

By virtue of the high COX-2 activity and/or specificity for COX-2 of the inhibitor derived from I over COX-1, Compound I will prove useful as an alternative to conventional NSAID's, particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking anticoagulants.

Similarly, Compound I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating COX-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a potentiator including caffeine; an H₂-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a prostaglandin including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment

- 15 -

a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

For the treatment of any of these cyclooxygenase mediated
5 diseases Compound I may be administered orally, topically, parenterally,
by inhalation spray or rectally in dosage unit formulations containing
conventional non-toxic pharmaceutically acceptable carriers, adjuvants
and vehicles. The term parenteral as used herein includes subcutaneous
10 injections, intravenous, intramuscular, intrasternal injection or infusion
techniques. In addition to the treatment of warm-blooded animals such as
mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the
invention is effective in the treatment of humans.

As indicated above, pharmaceutical compositions for
treating COX-2 mediated diseases as defined may optionally include one
15 or more ingredients as listed above.

The pharmaceutical compositions containing the active
ingredient may be in a form suitable for oral use, for example, as tablets,
troches, lozenges, aqueous or oily suspensions, dispersible powders or
granules, emulsions, hard or soft capsules, or syrups or elixirs.
20 Compositions intended for oral use may be prepared according to any
method known to the art for the manufacture of pharmaceutical
compositions and such compositions may contain one or more agents
selected from the group consisting of sweetening agents, flavoring agents,
coloring agents and preserving agents in order to provide
25 pharmaceutically elegant and palatable preparations. Tablets contain the
active ingredient in admixture with non-toxic pharmaceutically
acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be, for example, inert diluents, such as calcium
carbonate, sodium carbonate, lactose, calcium phosphate or sodium
30 phosphate; granulating and disintegrating agents, for example, corn
starch, or alginic acid; binding agents, for example starch, gelatin or
acacia, and lubricating agents, for example, magnesium stearate, stearic
acid or talc. The tablets may be uncoated or they may be coated by
known techniques to delay disintegration and absorption in the

- 16 -

gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and
5 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water
10 or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium
15 carboxymethylcellulose, methylcellulose, hydroxy-propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation
20 products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol
25 anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

30 Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth

- 17 -

above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxy-ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed

- 18 -

as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compound I may also be administered in the form of a
5 suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

10 For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula I are employed (for purposes of this application, topical application shall include mouth washes and gargles). Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer,
15 preservative system, and emollient.

Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by
20 the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending
25 upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit
30 forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including

- 19 -


the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The compounds of the present invention can be prepared
5 according to the following methods

METHOD A:

Treatment of a ketal 1 and a bistrimethylketene acetal 2 with a suitable Lewis acid such as TiCl_4 or $\text{Et}_2\text{O} \cdot \text{BF}_3$ in an appropriate solvent such as CH_2Cl_2 provides a adduct 3 as a diastereomeric mixture.
10 Esterification of 3 with CH_2N_2 followed by treatment with a base such as DBU gives rise to a mixture of 5 and 6 which are separated by silica gel chromatography. Oxidation of 5 with MMPP or mCPBA affords the desired product 7.


- 20 -



Method B:


Hydrolysis of ester 7 with a base such as LiOH or NaOH in a
aqueous solvent mixture such as THF/H₂O or MeOH/H₂O yields the
5 desired carboxylic acid 8.

- 21 -

Method C:

5

Treatment of carboxylic acid 8 with oxaly chloride followed by an appropriate amine afford the desired amide 9.



10


Method D:

A diphenyl lactone 10 is reduced to the diol 11 by a suitable
 15 reducing agent such as diisobutyl aluminum hydride or lithium aluminum
 hydride in an appropriate solvent such as toluene, hexane, tetrahydro-
 furan or ether. The diol 11 is alkylated with an alkyl halide or a benzyl
 halide in the presence of a base such as NaH or KOBut. This alkylation
 gives rise to the desired isomer 12 and the undesired isomer 13, which are
 20 separated by chromatography or crystallization. Compound 12 is
 oxidized to the aldehyde 14 by a reagent such as manganese dioxide.
 Further oxidation of 14 with NaClO₂ yields acid 15. Alternatively, 12


- 22 -

can be oxidized with Cr⁺⁶ reagents directly to acid 15. Base treatment of 15 generates the salt 16. Esters 17 can be prepared by reacting 15 with an alkylating agent in the presence of a base. The methyl ester of 15 is conveniently prepared on a small scale by the reaction of 15 with

5 diazomethane in ether.




- 23 -



- 24 -

Method E:

A diphenyl maleic anhydride 18 can be reduced to diol 11 with suitable hydride reducing agents such as di-isobutyl aluminum hydride or lithium aluminum hydride. Solvents such as toluene, tetrahydrofuran or ether, or a mixture thereof are suitable for the reduction.




- 25 -

Method F


The 2,3-diphenyl maleic anhydride 18 can be prepared by the method of Fields [*J. Org. Chem.*, vol. 55, pp. 5165-70 (1990); US 4,596,867] in which a phenylacetic acid 19s made to react with an α -oxophenylacetic acid 20 (preferably as its potassium salt) in refluxing acetic anhydride.

A multi-step sequence to 18 from phenylacetonitriles such as 21 and 22 is described by Smith, et. al., in *J. Org. Chem.*, vol. 55, pp. 3351-62 (1990).

Florac and co-workers in *Tetrahedron*, vol. 46, pp. 445-52 (1990) describe another synthesis of 18 in several steps from α -bromo phenylaceto hydrazides 23 and 24.



- 26 -







In Table I are shown some lactones **10** from which the compounds of the present invention can be prepared according to Method
 5 D.

In Table II and III are shown compounds representative of the present invention (structures Ia and Ib).





- 27 -

TABLE I

	Lactone
	1
	2
	3
	4





- 28 -

TABLE 1 (CONTINUED)

	Lactone
	5
	6
	7
	8





- 29 -

TABLE 1 (CONTINUED)

	Lactone
	9
	10
	11
	12





- 30 -

TABLE 1 (CONTINUED)

	Lactone
	13
	14
	15
	16





- 31 -

TABLE I (CONTINUED)

		Lactone
	17	
	18	
	19	
	20	





- 32 -

TABLE I (CONTINUED)

	Lactone
	21
	22
	23
	24





- 33 -

TABLE I (CONTINUED)

	Lactone
25	
	
26	
	
27	
	
28	





- 34 -

TABLE I (CONTINUED)

Lactone	
29	
30	
31	
32	





- 35 -

TABLE I (CONTINUED)

	Lactone
	33
	34
	35
	36





- 36 -

TABLE I (CONTINUED)

		Lactone
	37	
	38	
	39	
	40	




- 37 -

TABLE I (CONTINUED)

		Lactone
	41	
	42	
	43	
	44	


- 38 -

TABLE I (CONTINUED)

		Lactone
	45	
	46	
	47	

- 39 -

TABLE II




Ia

COMPOUND	R ²	R ³	X	Y
1	H	H	CH ₂ OH	CH ₃
2	H	H	CH ₂ OH	CH ₂ OMe
3	H	H	CHO	CH ₃
4	H	H	CO ₂ H	CH ₃
5	H	H	CO ₂ Me	CH ₃
6	H	H	CO ₂ Na	CH ₃
7	H	H	CHO	CH ₂ OMe
8	H	H	CO ₂ H	CH ₂ OMe
9	H	H	CO ₂ Me	CH ₂ OMe
10	H	H	CO ₂ Na	CH ₂ OMe
11	H	F	CH ₂ OH	CH ₃
12	H	F	CHO	CH ₂ OMe
13	H	F	CO ₂ Me	CH ₃
14	H	F	CO ₂ H	CH ₃
15	H	F	CO ₂ Na	CH ₃
16	F	F	CO ₂ H	CH ₃
17	F	F	CO ₂ Me	CH ₃
18	F	F	CO ₂ Me	CH ₂ OMe
19	F	F	CO ₂ Na	CH ₂ OMe
20	F	F	CH ₂ OH	CH ₃

- 40 -

TABLE III



Ib

COMPOUND	R ²	R ³	X	Y
21	H	H	CH ₂ OH	CH ₃
22	H	H	CH ₂ OH	CH ₂ OMe
23	H	H	CHO	CH ₃
24	H	H	CO ₂ H	CH ₃
25	H	H	CO ₂ Me	CH ₃
26	H	H	CO ₂ Na	CH ₃
27	H	H	CHO	CH ₂ OMe
28	H	H	CO ₂ H	CH ₂ OMe
29	H	H	CO ₂ Me	CH ₂ OMe
30	H	H	CO ₂ Na	CH ₂ OMe
31	H	F	CH ₂ OH	CH ₃
32	H	F	CHO	CH ₂ OMe
33	H	F	CO ₂ Me	CH ₃
34	H	F	CO ₂ H	CH ₃
35	H	F	CO ₂ Na	CH ₃

- 41 -

Assays for determining Biological Activity

The compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.

5

INHIBITION OF CYCLOOXYGENASE ACTIVITY

Compounds are tested as inhibitors of cyclooxygenase activity in whole cell cyclooxygenase assays. Both of these assays measure prostaglandin E₂ synthesis in response to arachidonic acid, using a radioimmunoassay. In these assays, 100% activity is defined as the difference between prostaglandin E₂ synthesis in the absence and presence of arachidonate.

15 Whole Cell Assays

For cyclooxygenase assays, osteosarcoma cells are cultured in 1 mL of media in 24-well multidishes (Nunc) until confluent (1-2 x 10⁵ cells/well). U-937 cells are grown in spinner flasks and resuspended to a final density of 1.5 x 10⁶ cells/mL in 24-well multidishes (Nunc). Following washing and resuspension of osteosarcoma and U-937 cells in 1 mL of HBSS, 1 µL of a DMSO solution of test compound or DMSO vehicle is added, and samples gently mixed. All assays are performed in triplicate. Samples are then incubated for 5 or 15 minutes at 37°C, prior to the addition of arachidonic acid. Arachidonic acid (peroxide-free, Cayman Chemical) is prepared as a 10 mM stock solution in ethanol and further diluted 10-fold in HBSS. An aliquot of 10 µL of this diluted solution is added to the cells to give a final arachidonic acid concentration of 10 µM. Control samples are incubated with ethanol vehicle instead of arachidonic acid. Samples are again gently mixed and incubated for a further 10 min. at 37°C. For osteosarcoma cells, reactions are then stopped by the addition of 100 µL of 1N HCl, with mixing and by the rapid removal of the solution from cell monolayers. For U-937 cells, reactions are stopped by the addition of 100 µL of 1N HCl, with mixing.

- 42 -

Samples are then neutralized by the addition of 100 μ L of 1N NaOH and PGE₂ levels measured by radioimmunoassay.

5 Whole cell assays for COX-2 and COX-1 using CHO transfected cell lines

Chinese hamster ovary (CHO) cell lines which have been stably transfected with an eukaryotic expression vector pCDNAIII containing either the human COX-1 or COX-2 cDNA's are used for the
10 assay. These cell lines are referred to as CHO [hCOX-1] and CHO [hCOX-2], respectively. For cyclooxygenase assays, CHO[hCOX-1] cells from suspension cultures and CHO[hCOX-2] cells prepared by trypsinization of adherent cultures are harvested by centrifugation (300 x g, 10 min) and washed once in HBSS containing 15 mM HEPES, pH 7.4,
15 and resuspended in HBSS, 15 mM HEPES, pH 7.4, at a cell concentration of 1.5×10^6 cells/ml. Drugs to be tested are dissolved in DMSO to 66.7-fold the highest test drug concentration. Compounds are typically tested at 8 concentrations in duplicate using serial 3-fold serial dilutions in DMSO of the highest drug concentration. Cells (0.3×10^6 cells in 200
20 μ L) are preincubated with 3 μ L of the test drug or DMSO vehicle for 15 min at 37°C. Working solutions of peroxide-free AA (5.5 μ M and 110 μ M AA for the CHO [hCOX-1] and CHO [COX-2] assays, respectively) are prepared by a 10-fold dilution of a concentrated AA solution in ethanol into HBSS containing 15 mM HEPES, pH 7.4. Cells are then
25 challenged in the presence or absence of drug with the AA/HBSS solution to yield a final concentration of 0.5 μ M AA in the CHO[hCOX-1] assay and a final concentration of 10 μ M AA in the CHO[hCOX-2] assay. The reaction is terminated by the addition of 10 μ L 1 N HCl followed by neutralization with 20 μ L of 0.5 N NaOH. The samples are
30 centrifuged at 300 x g at 4°C for 10 min, and an aliquot of the clarified supernatant is appropriately diluted for the determination of PGE₂ levels using an enzyme-linked immunoassay for PGE₂ (Correlate PGE₂ enzyme immunoassay kit, Assay Designs, Inc.). Cyclooxygenase activity in the absence of test compounds is determined as the difference in PGE₂

- 43 -

levels of cells challenged with arachidonic acid versus the PGE₂ levels in cells mock-challenged with ethanol vehicle. Inhibition of PGE₂ synthesis by test compounds is calculated as a percentage of the activity in the presence of drug versus the activity in the positive control samples.

5

Assay of COX-1 Activity from U937 cell microsomes

U 937 cells are pelleted by centrifugation at 500 x g for 5
10 min and washed once with phosphate-buffered saline and repelleted. Cells are resuspended in homogenization buffer consisting of 0.1 M Tris-HCl, pH 7.4, 10 mM EDTA, 2 µg/ml leupeptin, 2 µg/ml soybean trypsin inhibitor, 2 µg/ml aprotinin and 1 mM phenyl methyl sulfonyl fluoride. The cell suspension is sonicated 4 times for 10 sec and is centrifuged at
15 10,000 x g for 10 min at 4° C. The supernatant is centrifuged at 100,000 x g for 1 hr at 4 ° C. The 100,000 x g microsomal pellet is resuspended in 0.1 M Tris-HCl, pH 7.4, 10 mM EDTA to approximately 7 mg protein/ml and stored at -80° C.

20 Microsomal preparations are thawed immediately prior to use, subjected to a brief sonication, and then diluted to a protein concentration of 125 µg/ml in 0.1 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA, 0.5 mM phenol, 1 mM reduced glutathione and 1 µM hematin. Assays are performed in duplicate in a final volume of 250 µl.
25 Initially, 5 µl of DMSO vehicle or drug in DMSO are added to 20 µl of 0.1 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA in wells of a 96-deepwell polypropylene titre plate. 200 µl of the microsomal preparation are then added and pre-incubated for 15 min at room temperature before addition of 25 µl of 1 M arachidonic acid in 0.1 M Tris-HCl and 10 mM
30 EDTA, pH 7.4. Samples are incubated for 40 min at room temperature and the reaction is stopped by the addition of 25 µl of 1 N HCl. Samples are neutralized with 25 µl of 1 N NaOH prior to quantitation of PGE₂ content by radioimmunoassay (Dupont-NEN or Amersham assay kits). Cyclooxygenase activity is defined as the difference between PGE₂ levels

- 44 -

in samples incubated in the presence of arachidonic acid and ethanol vehicle.

Assay of the activity of purified human COX-2

5

The enzyme activity is measured using a chromogenic assay based on the oxidation of N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) during the reduction of PGG₂ to PGH₂ by COX-2 (Copeland et al. (1994) Proc. Natl. Acad. Sci. 91, 11202-11206).

10

Recombinant human COX-2 is purified from Sf9 cells as previously described (Percival et al (1994) Arch. Biochem. Biophys. 15, 111-118). The assay mixture (180 µL) contains 100 mM sodium phosphate, pH 6.5, 2 mM genapol X-100, 1 µM hematin, 1 mg/ml gelatin, 80-100 units of purified enzyme (One unit of enzyme is defined as the amount of enzyme required to produce an O.D. change of 0.001/min at 610 nm) and 4 µL of the test compound in DMSO. The mixture is pre-incubated at room temperature (22°C) for 15 minutes prior to initiation of the enzymatic reaction by the addition of 20 µL of a sonicated solution of 1 mM arachidonic acid (AA) and 1 mM TMPD in assay buffer (without enzyme or hematin). The enzymatic activity is measured by estimation of the initial velocity of TMPD oxidation over the first 36 sec of the reaction. A non-specific rate of oxidation is observed in the absence of enzyme (0.007 - 0.010 O.D. /min) and is subtracted before the calculation of the % inhibition. IC₅₀ values are derived from 4-parameter least squares non-linear regression analysis of the log-dose vs % inhibition plot.

30 HUMAN WHOLE BLOOD ASSAY

Rationale

Human whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory

- 45 -

compounds such as selective COX-2 inhibitors. Studies have shown that normal human blood does not contain the COX-2 enzyme. This is consistent with the observation that COX-2 inhibitors have no effect on PGE₂ production in normal blood. These inhibitors are active only after
5 incubation of human whole blood with LPS, which induces COX-2. This assay can be used to evaluate the inhibitory effect of selective COX-2 inhibitors on PGE₂ production. As well, platelets in whole blood contain a large amount of the COX-1 enzyme. Immediately following blood clotting, platelets are activated through a thrombin-mediated mechanism.
10 This reaction results in the production of thromboxane B₂ (TxB₂) via activation of COX-1. Thus, the effect of test compounds on TxB₂ levels following blood clotting can be examined and used as an index for COX-1 activity. Therefore, the degree of selectivity by the test compound can be determined by measuring the levels of PGE₂ after LPS induction
15 (COX-2) and TxB₂ following blood clotting (COX-1) in the same assay.

Method

A. COX-2 (LPS-induced PGE₂ production)

Fresh blood is collected in heparinized tubes by
20 venipuncture from both male and female volunteers. The subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. Plasma is immediately obtained from a 2mL blood aliquot to use as blank (basal levels of PGE₂). The remaining blood is incubated with LPS (100 µg/ml final concentration,
25 Sigma Chem, #L-2630 from E. coli; diluted in 0.1% BSA (Phosphate buffered saline) for 5 minutes at room temperature. Five hundred µL aliquots of blood are incubated with either 2µL of vehicle (DMSO) or 2µL of a test compound at final concentrations varying from 10nM to 30µM for 24 hours at 37°C. At the end of the incubation, the blood is
30 centrifuged at 12,000 x g for 5 minutes to obtain plasma. A 100µL aliquot of plasma is mixed with 400µL of methanol for protein precipitation. The supernatant is obtained and is assayed for PGE₂ using a radioimmunoassay kit (Amersham, RPA#530) after conversion of

- 46 -

PGE₂ to its methyl oximate derivative according to the manufacturer's procedure.

B. COX-1 (Clotting-induced TxB₂ production)

5 Fresh blood is collected into vacutainers containing no anticoagulants. Aliquots of 500µL are immediately transferred to siliconized microcentrifuge tubes preloaded with 2µL of either DMSO or a test compound at final concentrations varying from 10nM to 30µM. The tubes are vortexed and incubated at 37°C for 1 hour to allow blood to
10 clot. At the end of incubation, serum is obtained by centrifugation (12,000 x g for 5 min.). A 100µL aliquot of serum is mixed with 400µL of methanol for protein precipitation. The supernatant is obtained and is assayed for TxB₂ using a enzyme immunoassay kit (Cayman, #519031) according to the manufacturer's instruction.

15

RAT PAW EDEMA ASSAY

Protocol

20 Male Sprague-Dawley rats (150-200 g) are fasted overnight and are given, po, either vehicle (1% methocel or 5% Tween 80) or a test compound. One hr later, a line is drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (V₀) is measured using a plethysmometer
25 (Ugo-Basile, Italy) based on the principle of water displacement. The animals are then injected subplantarily with 50 µl of 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e. 500 µg carrageenan per paw). Three
30 hr later, the paw volume (V₃) is measured and the increases in paw volume (V₃ - V₀) are calculated. The animals are sacrificed by CO₂ asphyxiation and the absence or presence of stomach lesions scored. Data is compared with the vehicle-control values and percent inhibition calculated. All treatment groups are coded to eliminate observer bias.

- 47 -

NSAID-INDUCED GASTROPATHY IN RATS

Rationale

5 The major side effect of conventional NSAIDs is their ability to produce gastric lesions in man. This action is believed to be caused by inhibition of Cox-1 in the gastrointestinal tract. Rats are particularly sensitive to the actions of NSAIDs. In fact, rat models have been used commonly in the past to evaluate the gastrointestinal side effects of
10 current conventional NSAIDs. In the present assay, NSAID-induced gastrointestinal damage is observed by measuring fecal ^{51}Cr excretion after systemic injection of ^{51}Cr -labeled red blood cells. Fecal ^{51}Cr excretion is a well-established and sensitive technique to detect gastrointestinal integrity in animals and man.

15

Methods

Male Sprague Dawley rats (150 - 200 g) are administered orally a test compound either once (acute dosing) or b.i.d. for 5 days (chronic dosing). Immediately after the administration of the last dose,
20 the rats are injected via a tail vein with 0.5 mL of ^{51}Cr -labeled red blood cells from a donor rat. The animals are placed individually in metabolism cages with food and water *ad lib*. Feces are collected for a 48 h period and ^{51}Cr fecal excretion is calculated as a percent of total injected dose. ^{51}Cr -labeled red blood cells are prepared using the following procedures.
25 Ten mL of blood is collected in heparinized tubes via the vena cava from a donor rat. Plasma is removed by centrifugation and replenished with equal volume of HBSS. The red blood cells are incubated with 400 Ci of sodium ^{51}Cr chromate for 30 min. at 37C. At the end of the incubation, the red blood cells are washed twice with 20 mL HBSS to remove free
30 sodium ^{51}Cr chromate. The red blood cells are finally reconstituted in 10 mL HBSS and 0.5 mL of the solution (about 20 Ci) is injected per rat.

- 48 -

PROTEIN-LOSING GASTROPATHY IN SQUIRREL MONKEYS

Rationale

- Protein-losing gastropathy (manifested as appearance of circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to standard non-steroidal anti-inflammatory drugs (NSAIDs). This can be quantitatively assessed by intravenous administration of $^{51}\text{CrCl}_3$ solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum.
- Measurement of radioactivity appearing in feces collected for 24 h after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastropathy.

Methods

- Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with either 1% methocell or 5% Tween 80 in H₂O vehicles, (3mL/kg b.i.d.) or test compounds at doses from 1 - 100 mg/kg b.i.d. for 5 days. Intravenous ^{51}Cr (5Ci/kg in 1 ml/kg phosphate buffer saline (PBS)) is administered 1 h after the last drug/vehicle dose, and feces collected for 24 h in a metabolism cage and assessed for excreted ^{51}Cr by gamma-counting. Venous blood is sampled 1 h and 8 h after the last drug dose, and plasma concentrations of drug measured by RP-HPLC.

RAT PLASMA LEVELS

25

Per Os Pharmacokinetics in Rats

PROCEDURE:

- The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

Male Sprague Dawley rats (325-375 g) are fasted overnight prior to each PO blood level study.

- 49 -

5 The rats are placed in the restrainer one at a time and the box is firmly secured. The zero blood sample is obtained by nicking a small (1 mm or less) piece off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top to the bottom to milk out the blood. Approximately 1 mL of blood is collected into a heparinized vacutainer tube.

10 Compounds are prepared as required, in a standard dosing volume of 10mL/kg, and administered orally by passing a 16 gauge, 3" gavaging needle into the stomach.

15 Subsequent bleeds are taken in the same manner as the zero bleed except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and milked/stroked as described above into the appropriately labelled tubes.

20 Immediately after sampling, blood is centrifuged, separated, put into clearly marked vials and stored in a freezer until analysed.

Typical time points for determination of rat blood levels after PO dosing are:

25 0, 15min, 30min, 1h, 2h, 4h, 6h

After the 4hr time point bleed, food is provided to the rats *ad libitum*. Water is provided at all times during the study.

Vehicles:

30

The following vehicles may be used in PO rat blood level determinations:

PEG 200/300/400 - restricted to 2 mL/kg

Methocel 0.5% - 1.0% 10mL/kg

- 50 -

Tween 80 5% 10mL/kg

Compounds for PO blood levels can be in suspension form. For better dissolution, the solution can be placed in a sonicator for approximately 5 minutes.

Intravenous Pharmacokinetics in Rats

PROCEDURE:

10

The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

15

Male Sprague Dawley (325-375 g) rats are placed in plastic shoe box cages with a suspended floor, cage top, water bottle and food.

The compound is prepared as required, in a standard dosing volume of 1mL/kg.

20

Rats are bled for the zero blood sample and dosed under CO₂ sedation. The rats, one at a time, are placed in a primed CO₂ chamber and taken out as soon as they had lost their righting reflex. The rat is then placed on a restraining board, a nose cone with CO₂ delivery is placed over the muzzle and the rat restrained to the board with elastics. With the use of forceps and scissors, the jugular vein is exposed and the zero sample taken, followed by a measured dose of compound which is injected into the jugular vein. Light digital pressure is applied to the injection site, and the nose cone was removed. The time is noted. This constituted the zero time point.

25

30

The 5 min bleed is taken by nicking a piece (1-2 mm) off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top of the tail to the bottom to milk the blood out of the tail. Approximately 1 mL of blood is collected into a heparinized

- 51 -

collection vial. Subsequent bleeds are taken in the same fashion, except that there is no need to nick to tail again. The tail is cleaned with a piece of gauze and bled, as described above, into the appropriate labelled tubes.

5

Typical time points for determination of rat blood levels after I.V. dosing are either:

0, 5 min, 15min, 30min, 1h, 2h, 6h

or 0, 5 min, 30min, 1h, 2h, 4h, 6h.

10

Vehicles:

The following vehicles may be used in IV rat blood level determinations:

15 Dextrose: 1mL/kg

Molecusol 25%: 1mL/kg

DMSO: (Dimethylsulfoxide) Restricted to a dose volume of 0.1 mL per animal

PEG 200: Not more than 60% mixed with 40% sterile water - 1mL/kg

20

With Dextrose, either sodium bicarbonate or sodium carbonate can be added if the solution is cloudy.

25 For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection. Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability (F) is assessed by comparing area under the curve (AUC) i.v. versus p.o.

30

$$F = \frac{AUC_{po}}{AUC_{iv}} \times \frac{DOSE_{iv}}{DOSE_{po}} \times 100\%$$

35 Clearance rates are calculated from the following relation:

$$Cl = \frac{DOSE_{iv}(mg/kg)}{AUC}$$

- 52 -

AUCiv

The units of Cl are mL/h•kg (milliliters per hour kilogram)

5

Representative Biological Data

Compounds of the present invention are prodrugs of inhibitors of COX-2 and are thereby useful in the treatment of COX-2 mediated diseases as enumerated above. The extent of conversion of these compounds to the active COX-2 inhibitors may be seen in the representative results shown below. The plasma levels indicated are the maximum rat plasma concentrations of the active COX-2 inhibitor observed when the rat was treated with a 20 mg/kg oral dose of the indicated prodrug.

Table IV

Example	Plasma Levels (μM)*
1	1.0
* Maximum plasma concentration of the corresponding lactone observed in rats when dosed at 20 mg/kg orally with the indicated prodrug.	

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

25

- (i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C;
- (ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm Hg) with a bath temperature of up to 60°C;

30

- 53 -

- (iii) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only;
- 5 (iv) melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;
- 10 (v) the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data;
- (vi) yields are given for illustration only;
- 15 (vii) when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal;
- 20 (viii) chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), M.P. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles),
- 25 mmol (millimoles), eq (equivalent(s)).

EXAMPLE 1

(E)-3-(4-Methylsulfonyl)phenyl-2-phenylbut-2-enoic acid methyl ester

30 Step 1: 2-Methoxy-3-(4-methylthio)phenyl-2-phenylbutanoic acid methyl ester

To a solution of 1-(1,1-dimethoxyethyl)-4-methylthiobenzene (2.9 g, 13.7 mmol) in 100 mL of CH₂Cl₂ cooled at -78°C was added dropwise a solution of TiCl₄ (13.7 mL, 1M in CH₂Cl₂), followed by (2,2-

- 54 -

bistrimethylsilyloxyvinyl)benzene(4.6 g, 16.4 mmol, prepared according to the procedure published by Ainsworth, *J. Organomet. Chem.* **1972**, *46*, 73). The reaction mixture was stirred at -78°C for 2 h and quenched with pH 7 buffer solution(60 mL, NaH₂PO₄/Na₂HPO₄). The mixture was
5 extracted with 3x50 mL of CH₂Cl₂. The extracts were combined, dried over MgSO₄ and concentrated. The residue was dissolved in 50 mL of ether and treated with an excess of a solution of CH₂N₂ in ether. Evaporation of ether provided the crude title compound as a diastereomeric mixture.

10

Step 2: (E) and (Z)-3-(4-Methylsulfonyl)phenyl-2-phenylbut-2-enoic acid methyl ester

The crude product of Step 1(0.62 g) was dissolved in 10 mL of MeOH and cooled to 0°C. A solution of Oxone (4.0 mL, 0.75 M in
15 water) was added dropwise and the mixture was stirred at 0°C for 10 min and at r.t. for 2 h. The mixture was then diluted with water(10 mL) and extracted with 3x20 mL of CH₂Cl₂. The extracts were combined, dried over MgSO₄ and concentrated. The residue was dissolved in CH₃CN(10 mL) and treated with DBU(0.51 mL). The mixture was then heated to
20 reflux for 22 h and cooled to r.t.. The solvent was evaporated and the residue was purified by silica gel chromatography. Elution with 9:1 hexane/EtOAc first provided the desired *E*-isomer(0.25 g) as a white solid.

25 ¹H NMR(400 MHz, CDCl₃) δ 7.69 (2H, d), 7.20 (2H, d), 7.11 (3H, m), 6.96 (2H, m), 3.78 (3H, s), 2.97 (3H, s), 2.34 (3H, s).

Continuous elution with 4: 1 hexane/EtOAc afforded the *Z*-isomer (0.35 g) as a white solid.

30

¹H NMR(400 MHz, CDCl₃) δ 7.92 (2H, d), 7.48 (2H, d), 7.41 (2H, m), 7.33 (3H, m), 3.44 (3H, s), 3.07 (3H, s), 2.01 (3H, s).

EXAMPLE 2

35 (E)-3-(4-Methylsulfonyl)phenyl-2-phenylbut-2-enoic acid

- 55 -

A mixture of (*E*)-3-(4-methylsulfonyl)phenyl-2-phenyl-but-2-enoic acid methyl ester (258 mg) and LiOH·H₂O (98 mg) in 5 mL of dioxane and 5 mL of water was heated to reflux for 2 h. The reaction mixture was then cooled to r.t., acidified with 1 N HCl to pH~1, and extracted with 50 mL of EtOAc. The EtOAc layer was dried over Na₂SO₄ and concentrated. Crystallization from 1:1 hexane/EtOAc afforded the title acid (200 mg) as a white solid.

¹H NMR(400 MHz, CDCl₃) δ 7.69 (2H, d), 7.19 (2H, d), 7.13 (3H, m), 6.98 (2H, m), 2.97 (3H, s), 2.47 (3H, s).

EXAMPLE 3

(*E*)-2-(4-Fluorophenyl)-3-(4-methylsulfonyl)phenyl-but-2-enoic acid methyl ester

¹H NMR (400 MHz, acetone-d₆) δ 7.76 (2H, d), 7.36 (2H, d), 7.06 (2H, m), 6.90 (2H, m), 3.76 (3H, s), 3.05 (3H, s), 2.36 (3H, s).

EXAMPLE 4

(*E*)-3-(4-Methylsulfonyl)phenyl-1-morpholin-4-yl-2-phenylbut-2-en-1-one

The title compound was prepared according to the procedures described in Method C.

¹H NMR (400 MHz, CDCl₃) δ 7.73 (2H, d), 7.28 (2H, d), 7.13 (3H, m), 7.01 (2H, m), 3.72 (2H, m), 3.64 (2H, m), 3.42 (4H, bs), 3.00 (3H, s), 2.21 (3H, s).

EXAMPLE 5

(*E*)-4-Methoxy-3-(4-methylsulfonylphenyl)-2-phenylbutenoic acid

- 56 -


The title compound was prepared according to the procedures described in Method D.

- 5 ^1H NMR (400 MHz, acetone- d_6) δ 7.75 (2H, m), 7.42 (2H, d), 7.15 (5H, m), 4.55 (2H, s), 3.30 (3H, s), 3.05 (3H, s).

- 57 -

WHAT IS CLAIMED IS:

1. A compound of Formula I



I

5 or pharmaceutically acceptable salts thereof wherein

X is

- (a) CH₂OH,
 (b) CHO,
 10 (c) CO₂R⁴, or
 (d) CONR⁴₂;

Y is

- (a) CH₃, or
 (b) CH₂OR⁵;
 15 R¹ is selected from the group consisting of
 (a) S(O)₂CH₃,
 (b) S(O)₂NH₂,
 (c) S(O)₂NHC(O)CF₃,
 (d) S(O)(NH)CH₃,
 20 (e) S(O)(NH)NH₂,
 (f) S(O)(NH)NHC(O)CF₃,
 (g) P(O)(CH₃)OH, and
 (h) P(O)(CH₃)NH₂;

- 25 R² and R³ each are independently selected from the group consisting of
 (a) hydrogen,
 (b) halo,
 (c) C₁-6alkoxy,
 (d) C₁-6alkylthio,

- 58 -

- (e) CN,
- (f) CF₃,
- (g) C₁₋₆alkyl, and
- (h) N₃;

5 R⁴ is selected from the group consisting of

- (a) hydrogen,
- (b) C₁₋₆alkyl, and
- (c) mono- or disubstituted benzyl wherein the substituent is selected from

- 10 (1) hydrogen,
- (2) halo,
- (3) C₁₋₆alkyl,
- (4) C₁₋₆alkoxy,
- (5) C₁₋₆alkylthio,
- 15 (6) OH,
- (7) CN, and
- (8) CF₃,

or two R⁴ groups joined to the same N can form a saturated
5, 6 or 7-membered ring optionally containing an O or
20 S or an additional N atom, said N atom substituted by
a hydrogen or C₁₋₆ alkyl;

R⁵ is selected from the group consisting of

- (a) C₁₋₆alkyl,
- (b) mono- or disubstituted benzyl wherein the substituent is

25 selected from

- (1) hydrogen,
- (2) halo,
- (3) C₁₋₆alkyl,
- (4) C₁₋₆alkoxy,
- 30 (5) C₁₋₆alkylthio,
- (6) OH,
- (7) CN,
- (8) CF₃, and
- (9) CO₂R⁴.

35

- 59 -

2. A compound according to Claim 1 wherein
Y is CH₃ or CH₂OC₁₋₆alkyl;

3. A compound according to Claim 1 wherein
5 Y is CH₃ or CH₂OC₁₋₆alkyl;

R¹ is selected from the group consisting of

- (a) S(O)₂CH₃,
- (b) S(O)₂NH₂,
- (c) S(O)₂NHC(O)CF₃,
- 10 (d) S(O)NHCH₃,
- (e) S(O)NHNH₂, and
- (f) S(O)NHNHC(O)CF₃; and

R² and R³ are each independently selected from the group consisting of

- (a) hydrogen,
- 15 (b) fluoro, chloro, and bromo,
- (c) C₁₋₄alkoxy,
- (d) C₁₋₄alkylthio,
- (e) CN,
- (f) CF₃, and
- 20 (g) C₁₋₄alkyl.

4. A compound according to Claim 3 wherein
R² and R³ are each independently selected from the group consisting of

- (1) hydrogen, and
- 25 (2) halo;

R⁴ is hydrogen or methyl; and

R⁵ is C₁₋₆alkyl.

5. A compound according to Claim 4 wherein
30 R¹ is selected from the group consisting of

- (a) S(O)₂CH₃, and
- (b) S(O)₂NH₂;

R² and R³ are each independently selected from the group consisting of

- (1) hydrogen,

- 60 -


- (2) halo, selected from the group consisting of fluoro, chloro and bromo.

5 X is CO₂R⁴.
6. A compound according to Claim 1 wherein

7. A compound according to Claim 6 wherein
X is CO₂R⁴;
Y is methyl or CH₂OR⁵;
10 R¹ is S(O)₂CH₃;
R² and R³ each are independently selected from the group consisting of
(a) hydrogen, and
(b) halo;
R⁴ is selected from the group consisting of
15 (a) hydrogen, and
(b) C₁-6alkyl,
R⁵ is selected from the group consisting of
(a) C₁-6alkyl,
(b) mono- or disubstituted benzyl wherein the substituent is
20 selected from
(1) hydrogen,
(2) halo,
(3) C₁-6alkoxy, and
(4) OH.

25

8. A compound of formula Ia



- 61 -


Ia

wherein

	R ²	R ³	X	Y
1	H	H	CH ₂ OH	CH ₃
2	H	H	CH ₂ OH	CH ₂ OMe
3	H	H	CHO	CH ₃
4	H	H	CO ₂ H	CH ₃
5	H	H	CO ₂ Me	CH ₃
6	H	H	CO ₂ Na	CH ₃
7	H	H	CHO	CH ₂ OMe
8	H	H	CO ₂ H	CH ₂ OMe
9	H	H	CO ₂ Me	CH ₂ OMe
10	H	H	CO ₂ Na	CH ₂ OMe
11	H	F	CH ₂ OH	CH ₃
12	H	F	CHO	CH ₂ OMe
13	H	F	CO ₂ Me	CH ₃
14	H	F	CO ₂ H	CH ₃
15	H	F	CO ₂ Na	CH ₃
16	F	F	CO ₂ H	CH ₃
17	F	F	CO ₂ Me	CH ₃
18	F	F	CO ₂ Me	CH ₂ OMe
19	F	F	CO ₂ Na	CH ₂ OMe
20	F	F	CH ₂ OH	CH ₃

- 62 -

9. A compound of formula Ib



Ib

wherein

	R ²	R ³	X	Y
1	H	H	CH ₂ OH	CH ₃
2	H	H	CH ₂ OH	CH ₂ OMe
3	H	H	CHO	CH ₃
4	H	H	CO ₂ H	CH ₃
5	H	H	CO ₂ Me	CH ₃
6	H	H	CO ₂ Na	CH ₃
7	H	H	CHO	CH ₂ OMe
8	H	H	CO ₂ H	CH ₂ OMe
9	H	H	CO ₂ Me	CH ₂ OMe
10	H	H	CO ₂ Na	CH ₂ OMe
11	H	F	CH ₂ OH	CH ₃
12	H	F	CHO	CH ₂ OMe
13	H	F	CO ₂ Me	CH ₃
14	H	F	CO ₂ H	CH ₃
15	H	F	CO ₂ Na	CH ₃

5

10. A compound according to Claim 1 selected from

- (a) (*E*)-3-(4-Methylsulfonyl)phenyl-2-phenylbut-2-enoic acid methyl ester,
- (b) (*E*)-3-(4-Methylsulfonyl)phenyl-2-phenylbut-2-enoic acid,
- 10 (c) (*E*)-2-(4-Fluorophenyl)-3-(4-methylsulfonyl)phenyl-but-2-enoic acid methyl ester,
- (d) (*E*)-3-(4-Methylsulfonyl)phenyl-1-morpholin-4-yl-2-phenylbut-2-en-1-one, and

- 63 -

(e) (E)-4-Methoxy-3-(4-methylsulfonylphenyl)-2-phenylbutenoic acid.

5 11. A pharmaceutical composition for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising:

a non-toxic therapeutically effective amount of a compound according to any one of Claims 1 to 10 and a pharmaceutically acceptable carrier.

10 12. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

15 a non-toxic therapeutically effective amount of a compound according to any one of Claims 1 to 10 and a pharmaceutically acceptable carrier.

13. A method of treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising:

20 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

25 14. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1.

- 64 -

15. An anti-inflammatory pharmaceutical composition comprising an acceptable, anti-inflammatory amount of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or a pharmaceutically acceptable salt thereof, in association with a
5 pharmaceutically acceptable carrier.

16. A compound of formula (I), as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or a pharmaceutically acceptable salt thereof, for use in treating cyclooxygenase mediated diseases advantageously treated by an agent that selectively inhibits COX-2 in preference to
10 COX-1.

17. Use of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-
15 inflammatory agent.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 97/00063

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C317/44 C07C317/46 C07D295/18 A61K31/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 00501 A (MERCK FROSST CANADA) 5 January 1995 cited in the application see the whole document ---	1,11-14
A	US 5 393 790 A (D.B. REITZ, ET AL.) 28 February 1995 see column 56, line 14 - line 37 ---	1
A	EP 0 424 541 A (OTSUKA PHARMACEUTICAL FACTORY) 2 May 1991 cited in the application see page 2 -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 April 1997

Date of mailing of the international search report

02.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 97/00063

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 13,14
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00063

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9500501 A	05-01-95	US 5474995 A	12-12-95
		AU 6197096 A	31-10-96
		AU 6967494 A	17-01-95
		BG 100247 A	28-06-96
		BR 9406979 A	05-03-96
		CA 2163888 A	05-01-95
		CA 2176973 A	25-12-94
		CA 2176974 A	25-12-94
		CN 1125944 A	03-07-96
		CZ 9503146 A	15-05-96
		EP 0705254 A	10-04-96
		EP 0754687 A	22-01-97
		FI 956119 A	19-12-95
		HR 940373 A	31-12-96
		JP 9500372 T	14-01-97
		NO 955256 A	23-02-96
		PL 312196 A	01-04-96
		SK 150295 A	08-01-97
		US 5536752 A	16-07-96
		US 5550142 A	27-08-96
		ZA 9404501 A	13-03-95
		AU 1269495 A	01-08-95
		BG 100350 A	31-12-96
		CA 2180651 A	13-07-95
		WO 9518799 A	13-07-95
		CN 1143365 A	19-02-97
		EP 0739340 A	30-10-96
		FI 962800 A	06-09-96
		NO 960393 A	09-07-96
US 5393790 A	28-02-95	AU 1740895 A	29-08-95
		CA 2182950 A	17-08-95
		EP 0743938 A	27-11-96
		WO 9521817 A	17-08-95
		ZA 9501107 A	12-02-96
EP 424541 A	02-05-91	AU 625123 B	02-07-92
		AU 5435690 A	16-11-90
		CA 2032489 A	25-10-90
		WO 9012786 A	01-11-90

Information on patent family members

PCT/CA 97/00063

Form PCT/ISA/210 (patent family annex) (July 1992)